title: Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments.
abstract: Melioidosis is a life-threatening bacterial infection caused by Burkholderia pseudomallei. Some antibiotics used to treat melioidosis can induce filamentation in B. pseudomallei. Despite studies on the mechanism of virulence of the bacteria, the properties of B. pseudomallei filaments and their impact on virulence have not been investigated before. To understand the characteristics of antibiotic-induced filaments, we performed in vitro assays to compare several aspects of virulence between normal, nonfilamentous and filamentous B. pseudomallei. Normal, nonfilamentous B. pseudomallei could cause the lysis of monocytic cells, while filaments induced by sublethal concentrations of ceftazidime, ofloxacin, or trimethoprim show decreased lysis of monocytic cells, especially after prolonged antibiotic exposure. The motility of the filamentous bacteria was reduced compared to that of nonfilamentous bacteria. However, the filamentation was reversible when the antibiotics were removed, and the revertant bacteria recovered their motility and ability to lyse monocytic cells. Meanwhile, antibiotic resistance developed in revertant bacteria exposed to ceftazidime at the MIC. Our study highlights the danger of letting antibiotic concentration drop to the MIC or sub-MICs during antibiotic treatment of melioidosis. This could potentially give rise to a temporary reduction of bacterial virulence, only to result in bacteria that are equally virulent but more resistant to antibiotics, should the antibiotics be reduced or removed.
authors.affiliation: Department of Biochemistry, National University of Singapore, 8 Medical Dr., Singapore 117597, Singapore.
authors.forename: Kang
authors.initials: K
authors.lastname: Chen
authors.forename: Guang Wen
authors.initials: GW
authors.lastname: Sun
authors.forename: Kim Lee
authors.initials: KL
authors.lastname: Chua
authors.forename: Yunn-Hwen
authors.initials: YH
authors.lastname: Gan
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016957:Burkholderia pseudomallei / Q000187:drug effects* / Q000472:pathogenicity / Q000648:ultrastructure; D002460:Cell Line; D016207:Cytokines / Q000096:biosynthesis; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D014774:Virulence
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines
references.citation: Curr Opin Infect Dis. 2004 Apr;17(2):131-6
references.pmid: 15021053
references.citation: Antimicrob Agents Chemother. 1999 May;43(5):1013-9
references.pmid: 10223908
references.citation: Antimicrob Agents Chemother. 1977 Dec;12(6):736-44
references.pmid: 337891
references.citation: Rev Infect Dis. 1979 May-Jun;1(3):434-67
references.pmid: 45147
references.citation: J Antimicrob Chemother. 1981 Jan;7(1):57-63
references.pmid: 7009535
references.citation: J Antimicrob Chemother. 2000 Jan;45(1):15-25
references.pmid: 10629008
references.citation: J Infect Dis. 2000 Mar;181(3):1014-9
references.pmid: 10720525
references.citation: Med Microbiol Immunol. 1999 Nov;188(2):91-7
references.pmid: 10753061
references.citation: Br J Clin Pharmacol. 2000 Aug;50(2):184-91
references.pmid: 10930972
references.citation: Cell Microbiol. 2000 Aug;2(4):265-73
references.pmid: 11207583
references.citation: Microbiol Immunol. 2001;45(4):307-13
references.pmid: 11386421
references.citation: Infect Immun. 2002 Feb;70(2):504-11
references.pmid: 11796576
references.citation: Curr Opin Infect Dis. 2002 Apr;15(2):127-32
references.pmid: 11964912
references.citation: J Chemother. 1991 Jan;3 Suppl 1:105-11
references.pmid: 12041741
references.citation: Infect Immun. 2003 Apr;71(4):1622-9
references.pmid: 12654773
references.citation: Chest. 2004 Feb;125(2 Suppl):62S-69S; quiz 69S
references.pmid: 14872002
references.citation: Antimicrob Agents Chemother. 1981 May;19(5):901-10
references.pmid: 6271051
references.citation: J Med Microbiol. 1987 Feb;23(1):83-8
references.pmid: 3546699
references.citation: Rev Infect Dis. 1989 May-Jun;11(3):413-25
references.pmid: 2665001
references.citation: J Infect Dis. 1992 Mar;165(3):561-4
references.pmid: 1538161
references.citation: J Infect Dis. 1992 Jun;165(6):1033-41
references.pmid: 1583320
references.citation: Scand J Infect Dis. 1991;23(6):745-54
references.pmid: 1815338
references.citation: Nature. 1992 Jul 9;358(6382):167-9
references.pmid: 1614548
references.citation: Infect Immun. 1994 Nov;62(11):4975-80
references.pmid: 7927777
references.citation: Eur J Clin Microbiol Infect Dis. 1994;13 Suppl 1:S43-51
references.pmid: 7821304
references.citation: J Med Microbiol. 1995 May;42(5):362-6
references.pmid: 7752216
references.citation: J Infect Dis. 1995 Dec;172(6):1519-27
references.pmid: 7594711
references.citation: Antimicrob Agents Chemother. 1995 Oct;39(10):2356-8
references.pmid: 8619598
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4197-201
references.pmid: 8633040
references.citation: J Antimicrob Chemother. 1996 Jan;37(1):188-90
references.pmid: 8647763
references.citation: J Antimicrob Chemother. 1995 Dec;36(6):885-7
references.pmid: 8821587
references.citation: Infect Immun. 1996 Dec;64(12):4952-9
references.pmid: 8945532
references.citation: J Exp Med. 1998 Apr 6;187(7):1069-79
references.pmid: 9529323
references.citation: Annu Rev Microbiol. 1998;52:591-625
references.pmid: 9891809
references.citation: J Ultrastruct Res. 1969 Jan;26(1):31-43
references.pmid: 4887011